# Efficacy and Safety of HRS-7535 Tablets in Adults With Diabetic Kidney Disease in Type 2 Diabetes

Study · id `cardio:ct-nct06415214` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06415214](<https://clinicaltrials.gov/study/NCT06415214>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06415214

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 281 participants.

## Technical summary

Registry record NCT06415214. Randomized; quadruple masking; primary purpose treatment. Start 2024-06-21 (actual); primary completion 2025-07-15 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 281 participants (enrolled count; ClinicalTrials.gov record NCT06415214, source copy `cardio:ctgov-nct06415214-2026-01-05`, retrieved 2026-10-26)
- Started: 2024-06-21 (actual) (ClinicalTrials.gov record NCT06415214, source copy `cardio:ctgov-nct06415214-2026-01-05`, retrieved 2026-10-26)
- Primary completion: 2025-07-15 (actual) (ClinicalTrials.gov record NCT06415214, source copy `cardio:ctgov-nct06415214-2026-01-05`, retrieved 2026-10-26)
- Completion: 2025-07-25 (actual) (ClinicalTrials.gov record NCT06415214, source copy `cardio:ctgov-nct06415214-2026-01-05`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06415214, source copy `cardio:ctgov-nct06415214-2026-01-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06415214-2026-01-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of HRS-7535 Tablets in Adults With Diabetic Kidney Disease in Type 2 Diabetes
- Acronym: SOLID-DKD
- Condition: Diabetic Kidney Disease, Type 2 Diabetes
- Intervention (Drug): Placebo
- Intervention (Drug): HRS-7535
- Lead sponsor: Shandong Suncadia Medicine Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Diabetic kidney disease (`cardio:diabetic-nephropathy`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Shandong Suncadia Medicine Co., Ltd. (`cardio:org-shandong-suncadia-medicine-co-ltd`)

## Provenance

Content hash: b524dde14bd5580dded641fd3f31be8ad26bda663f3b6d8520396a264f3cabef
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
